

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/833,017	04/10/2001	Dennis Cvitkovitch	1889-00401	8365
	590 06/12/2002			
CONLEY ROSE & TAYON, P.C.			EXAMINER	
	P. O. BOX 3267 HOUSTON, TX 7.7253-3267		BASKAR, PADMAVATHI	
			ART UNIT	PAPER NUMBER
			1645	100
			DATE MAILED: 06/12/2002	10

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	n No. Applicant(s)			
Office Action Summany	09/833,017	CVITKOVITCH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Padmavathi v Baskar	1645			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1) Responsive to communication(s) filed on	<u> </u>				
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-6 and 21-33</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)☐ Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1-6 and 21-33 are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accep	ted or b)⊡ objected to <b>by</b> t	he Examiner.			
Applicant may not request that any objection to the	drawing(s) be held in abeya	ance. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ d	isapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:		·			
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
<ul> <li>a)          The translation of the foreign language provisional application has been received.     </li> <li>15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>					
Attachment(s)					
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of I	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)			

Application/Control Number: 09/833,017

Art Unit: 1645

## RESTRICTION

- 1. Applicant's preliminary amendment filed on 9/27/01 is acknowledged. Claims 7-21 and 34-37 have been canceled. Claims 3-6, 24, 29,30 and 32 have been amended. Claims 1-6 and 22-33 are pending in the application.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claim 1 -5, 22-28, 32-33 drawn to polypeptide classified in class 530, subclass
     350. Further election of invention required
  - II Claims 29 drawn to DNA. classified in class 536, subclass 23.7 Further election of invention required.
  - Claims 1-5 and 30 drawn to an antibody classified in class 530, subclass 388.6 Further election of invention required.
  - IV Claim 6 drawn to a method of treatment of caries or endocarditis using peptide classified in class 435, subclass 6. Further election of invention required.
  - V Claim 6 drawn to a method of treatment of caries or endocarditis using an antibody classified in class 424 subclass 130.1 Further election of invention required.
- 3. The inventions are distinct, each from the other because of the following reasons:
  Group I is directed polypeptide, which are made of amino acids. Group II is directed to
  DNA, which consists of nucleic acids. Invention III is drawn to an antibody

Thus, these products are different each other structurally, biochemically and functionally.

4. Invention I is related to invention IV as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using

Application/Control Number: 09/833,017

Art Unit: 1645

Page 3

the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the protein of Group I can be used in immunoaffinity chromatography-methods for purifying antibodies and need not be used in the invention IV.

5. Invention III is related to inventions V as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of Group III can be used in immunoaffinity chromatography for purifying antigens and need not be used in the invention V.

## Distinct inventions

- 6. Groups I-V contain claims reciting patentably distinct inventions with distinct SEQ.ID.NOS 2 or 4. Applicant is advised to elect one SEQ.ID.NO from any one of the groups.
- 7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their separate classification and their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 8. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the SEQ.ID.NOS to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 9. Applicant is advised that the response to this requirement to be complete must include an election of the invention with one SEQ.ID.NO to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1645

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Padmavathi v Baskar whose telephone number is (703) 308-8886. The examiner can normally be reached on M-F (6:30A.M-4: 00 P.M.) First Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (703) 308-3909. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

P. Baskar Ph.D. 6/7/02

LYNETTE R.F. SMITH SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600